Loading...
Market
Will Adaptimmune's TECELRA® achieve full FDA approval by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA® for Advanced Synovial Sarcoma
Aug 1, 2024, 06:03 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking it as the first approved engineered cell therapy for a solid tumor. This milestone approval extends the power of immunotherapies into difficult-to-reach sarcomas, specifically targeting advanced synovial sarcoma, a rare cancer that arises in the body's soft tissues. Adaptimmune's TECELRA® is also noted as a significant development in TCR gene therapy.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
